1 Bagadi S A R, Prasad C P, Srivastava A, et al. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer[J]. Breast Cancer Research and Treatment, 2007, 104(3): 277~286.2 Cui M, Liu Z H, Qin Q, et al. Tumour induction in rats following exposure to short-term high dose aristolochic acid Ⅰ[J]. Mutagenesis, 2005, 20(1): 45~49.3 Debelle F D, Vanherweghem J L. Aristolochic acid nephropathy: A worldwide problem[J]. Kidney Int, 2008, 74(2): 158~169.4 Depierreux M, Van Damme B, Vanden Houte K, et al. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs[J]. Am J Kidney Dis, 1994, 24(2): 172~180.5 Grollman A P, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy[J]. Proc Natl Acad Sci USA, 2007, 104: 12129~12134.6 Hocevar B A, Smine A, Xu X X, et al. The adaptor molecule Disabled-2 links the transforming growth factor β receptors to the Smad pathway[J]. The EMBO Journal, 2001, 20(11): 2789~2801.7 Hocevar B A, Mou F, Rennolds J L, et al. Regulation of the Wnt signaling pathway by disabled-2 (Dab2)[J]. The EMBO Journal, 2003, 22(12): 3084~3094.8 Hocevar B A, Prunier C, Howe P H, et al. Disabled-2 (Dab2) mediates transforming growth factor β(TGF-β)-stimulated fibronectin synthesis through TGF-β-activated kinase 1 and activation of the JNK pathway[J]. Journal of Biological Chemistry, 2005, 280: 25920~25927.9 Karam J A, Shariat S F, Huang H Y, et al. Decreased DOC-2/DAB-2 expression in urothelial caricinoma of the bladder[J]. Clin Cancr Res, 2007, 13: 4400~4406.10 Lemy A, Wissing K M, Rorive S, et al. Late onset of bladder urothelial carcinoma after renal transplantation for end-stage aristolochic acid nephropathy: A case series with 15-year follow-up[J]. Am J Kidney Dis, 2008, 51(3): 471~477.11 Li J, Zhang Z, Wu G, et al. TGF-β1/Smads signaling stimulates renal interstitial fibrosis in experimental AAN[J]. Journal of Receptors and Signal Transduction, 2009, 29(5): 280~285.12 Lord G M, Hollstein M, Arlt V M, et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy[J]. American Journal of Kidney Disease, 2004, 43(4): 11~17.13 Mishra S K, Keyel P A, Hawryluk M J, et al. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor[J]. The EMBO Journal, 2002, 21: 4915~4926.14 Mok S C, Wong K K, Chan R K W, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer[J]. Gynecologic Oncology, 1994, 52(2): 247~252.15 Morris S M, Cooper J A. Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2[J]. Traffic, 2001, 2: 111~123.16 Nagai J, Christensen E I, Morris S M, et al. Mutually dependent localization of megalin and Dab2 in the renal proximal tubule[J]. Am J Physiol Physiol, 2005, 289: 569~576.17 Penheiter S G, Singh R D, Repellin C E, et al. Type Ⅱ transforming growth factor-β receptor recycling is dependent upon the clathrin adaptor protein Dab2[J]. Molecular Biology of the Cell, 2010, 21: 4009~4019.18 Pozdzik A A, Salmon I J, Debelle F D, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation[J]. Kidney Int, 2008a, 73: 595~607.19 Pozdzik A A, Salmon I J, Husson C P, et al. Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy[J]. Nephrol Dial Transplant, 2008b, 23: 2480~2491.20 Prunier C, Howe P H. Disabled-2 (Dab2) is required for transforming growth factor β-induced epithelial to mesenchymal transition (EMT)[J]. J Biol Chem, 2005, 280: 17540~17548.21 Schmeiser H H, Bieler C A, Weissler M, et al. Detection of DNA adducts formed by aristolchic acid in renal tissue from patients with Chinese herbs nephropathy[J]. Cancer Res, 1996, 56: 2025~2028.22 Shibutani S, Dong H, Suzuki N, et al. Selective toxicity of aristolochic acids Ⅰ and Ⅱ[J]. Drug Metab Dispos, 2007, 35: 1217~1222.23 Vanherweghem J L. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including chinesis herbs[J]. Lancet, 1993, 341: 387.24 Vanherweghem J L, Tielemans C, Simon J, et al. Chinese herbs nephropathy and renal pelvic carcinoma[J]. Nephrol Dial Transplant, 1995, 10: 270~273.25 Yan X H, Chen Y G. Smad7: Not only a regulator, but also a cross-talk mediator of TGF-β signalling[J]. Biochem, 2011, 434: 1~10.26 Yang F, Chung A C, Huang X R, et al. Angiotensin Ⅱ induces connective tissue growth factor and collagen Ⅰ expression via transforming growth factor-beta-dependent and-independent Smad pathways: The role of Smad3[J]. Hypertension, 2009, 54: 877~884. |